Privacy Policy

Wednesday, March 4, 2020

Diets & Weight Loss

  Diets & Weight Loss

 

CUSTOM KETO DIET






1- Supports weight loss
2-Improves acne
3-May reduce risk of certain cancers
Top of Form
Bottom of Form
4-May improve heart health
5- May protect brain function
6- Potentially reduces seizures
7-Improves PCOS symptoms
Keto diet is one of the best diet to lose weight fast but also to keep you healthy.

Tuesday, March 3, 2020

How Vitamin C Stops Cancer.

How Vitamin C Stops Cancer.

Image result for vitamin c
 
Nearly 30 years after Nobel laureate Linus Pauling famously and controversially suggested that vitamin C supplements can prevent cancer, a team of Johns Hopkins scientists have shown that in mice at least, vitamin C - and potentially other antioxidants - can indeed inhibit the growth of some tumors ¯ just not in the manner suggested by years of investigation.
The conventional wisdom of how antioxidants such as vitamin C help prevent cancer growth is that they grab up volatile oxygen free radical molecules and prevent the damage they are known to do to our delicate DNA. The Hopkins study, led by Chi Dang, M.D., Ph.D., professor of medicine and oncology and Johns Hopkins Family Professor in Oncology Research, unexpectedly found that the antioxidants' actual role may be to destabilize a tumor's ability to grow under oxygen-starved conditions. Their work is detailed this week in Cancer Cell.
"The potential anticancer benefits of antioxidants have been the driving force for many clinical and preclinical studies," says Dang. "By uncovering the mechanism behind antioxidants, we are now better suited to maximize their therapeutic use."
"Once again, this work demonstrates the irreplaceable value of letting researchers follow their scientific noses wherever it leads them," Dang adds.
The authors do caution that while vitamin C is still essential for good health, this study is preliminary and people should not rush out and buy bulk supplies of antioxidants as a means of cancer prevention.
The Johns Hopkins investigators discovered the surprise antioxidant mechanism while looking at mice implanted with either human lymphoma (a blood cancer) or human liver cancer cells. Both of these cancers produce high levels of free radicals that can be suppressed by feeding the mice supplements of antioxidants, either vitamin C or N-acetylcysteine (NAC).
However, when the Hopkins team examined cancer cells from cancer-implanted mice not fed the antioxidants, they noticed the absence of any significant DNA damage. "Clearly, if DNA damage was not in play as a cause of the cancer, then whatever the antioxidants were doing to help was also not related to DNA damage," says Ping Gao, Ph.D, lead author of the paper.go to >>>Take vitamin C today.
             
      

That conclusion led Gao and Dang to suspect that some other mechanism was involved, such as a protein known to be dependent on free radicals called HIF-1 (hypoxia-induced factor), which was discovered over a decade ago by Hopkins researcher and co-author Gregg Semenza, M.D., Ph.D., director of the Program in Vascular Cell Engineering. Indeed, they found that while this protein was abundant in untreated cancer cells taken from the mice, it disappeared in vitamin C-treated cells taken from similar animals.
"When a cell lacks oxygen, HIF-1 helps it compensate," explains Dang. "HIF-1 helps an oxygen-starved cell convert sugar to energy without using oxygen and also initiates the construction of new blood vessels to bring in a fresh oxygen supply."
Some rapidly growing tumors consume enough energy to easily suck out the available oxygen in their vicinity, making HIF-1 absolutely critical for their continued survival. But HIF-1 can only operate if it has a supply of free radicals. Antioxidants remove these free radicals and stop HIF-1, and the tumor, in its tracks.
The authors confirmed the importance of this "hypoxia protein" by creating cancer cells with a genetic variant of HIF-1 that did not require free radicals to be stable. In these cells, antioxidants no longer had any cancer-fighting power.
The research was funded by the National Institutes of Health.
Authors on the paper are Dean Felsher of Stanford; and Gao, Huafeng Zhang, Ramani Dinavahi, Feng Li, Yan Xiang, Venu Raman, Zaver Bhujwalla, Linzhao Cheng, Jonathan Pevsner, Linda Lee, Gregg Semenza and Dang of Johns Hopkins. go to >>>Take vitamin C today. 

Story Source:
Materials provided by Johns Hopkins Medical Institutions. Note: Content may be edited for style and length.

Vitamin C Lowers Levels Of Inflammation Biomarker Considered Predictor Of Heart Disease

 

Vitamin C Lowers Levels Of Inflammation Biomarker Considered Predictor Of Heart Disease

Image result for vitamin c
 
go to >>vitamin C
For people who have elevated levels of C-reactive protein, a predictor of heart disease, taking vitamin C supplements can help lower levels of the inflammation biomarker, according to a new study. The new findings come just days after a major, eight-year clinical trial failed to show that vitamin C or E could cut the risk of heart attacks or strokes.
A new study led by researchers at the University of California, Berkeley, adds to the evidence that vitamin C supplements can lower concentrations of C-reactive protein (CRP), a central biomarker of inflammation that has been shown to be a powerful predictor of heart disease and diabetes. The same study found no benefit from daily doses of vitamin E, another antioxidant.
This study comes just days after a larger, eight-year clinical trial led by researchers at Boston's Brigham and Women's Hospital failed to show that vitamin C  or E could cut the risk of heart attacks or strokes.
That trial does not necessarily close the books on the benefits of vitamin C for cardiovascular health, according to Gladys Block, UC Berkeley professor emeritus of epidemiology and public health nutrition and lead author of the study looking at vitamins C and E and their impact on CRP levels. She pointed out that the Brigham and Women's Hospital study did not screen study participants for elevations in CRP - defined by the American Heart Association as 1 milligram per liter or greater - which is an important distinction in determining who might benefit from taking vitamin C .
The study led by Block, currently online and scheduled to appear in the Jan. 1 issue of the journal Free Radical Biology and Medicine, shows that for healthy, non-smoking adults with an elevated level of CRP, a daily dose of vitamin C lowered levels of the inflammation biomarker after two months compared with those who took a placebo. However, participants who did not start out with elevated CRP levels saw no benefit from vitamin C supplementation.
"This is an important distinction; treatment with vitamin C is ineffective in persons whose levels of CRP are less than 1 milligram per liter, but very effective for those with higher levels," said Block. "Grouping people with elevated CRP levels with those who have lower levels can mask the effects of vitamin C. Common sense suggests, and our study confirms, that biomarkers are only likely to be reduced if they are not already low."
The researchers said that for people with elevated CRP levels, the amount of CRP reduction achieved by taking vitamin C supplements in this study is comparable to that in many other studies of cholesterol-lowering drugs called statins. They noted that several larger statin trials lowered CRP levels by about 0.2 milligrams per liter; in this latest study, vitamin C lowered CRP by 0.25 milligrams per liter.
     

"This finding of an effect of vitamin C is important because it shows in a carefully conducted randomized, controlled trial that for people with moderately elevated levels of inflammation, vitamin C may be able to reduce CRP as much as statins have done in other studies," said Block.
Evidence of the link between elevated CRP levels and a greater risk of heart disease has grown in recent years, but it had been unclear whether the beneficial effects of lowering CRP were independent of the effects of lowering cholesterol.
Newly released results from a multinational clinical trial help answer that question. Led by researchers at Harvard Medical School, the study, known as the Jupiter trial, found that statins reduced cardiovascular mortality and morbidity among people whose cholesterol levels were normal, but whose levels of CRP were greater than 2 milligrams per liter. The Jupiter trial found that among people who had such high levels of CRP at baseline, levels of CRP were 37 percent lower with statins compared with a placebo.
"One of the strengths of the Jupiter trial is that only persons with CRP levels greater than 2 milligrams per liter were enrolled," Block added. "Researchers found very important effects of lowering CRP in people who had high levels to begin with."
In the UC Berkeley study on vitamin C , participants who started out with CRP levels greater than 2 milligrams per liter had 34 percent lower levels of CRP with vitamin C compared with a placebo.
            

The UC Berkeley study also found a strong link between obesity and elevated levels of CRP. The researchers found that while 25 percent of normal-weight people had elevated levels of CRP, those levels were found in 50 percent of overweight and 75 percent of obese participants.
"The low-grade inflammation that characterizes obesity is believed to contribute to a number of disorders, including atherosclerosis and insulin resistance," said Nina Holland, adjunct professor at UC Berkeley's Division of Environmental Health Sciences and co-investigator on the study. Holland's biorepository at UC Berkeley processed and stored the thousands of blood samples involved in this study.
Notably, the American Heart Association and the U.S. Centers for Disease Control and Prevention recommends that clinicians measure CRP levels in patients who have a moderately elevated risk of cardiovascular problems, as determined by other established risk factors such as high cholesterol levels and smoking.
"Major studies have found that the level of CRP in the body predicts future risk of cardiovascular disease, including myocardial infarction, stroke and peripheral artery disease, as well as diabetes," said Block. "Some believe CRP to be as important a predictor of future heart problems as high levels of LDL and low levels of HDL cholesterol."
The UC Berkeley-led study looked at the separate effects of two antioxidants: vitamin C and vitamin E. The researchers randomly divided 396 healthy, non-smoking adults from the San Francisco Bay Area into groups taking daily doses of either 1,000 milligrams of vitamin C, 800 international units of vitamin E or a placebo. The recommended dietary allowance (RDA) for vitamin C is 90 milligrams per day for men and 75 milligrams per day for women. The researchers noted that the suggested upper limit for vitamin C is 2,000 milligrams per day, or twice the level used in the study.
They compared participants' baseline CRP levels with their levels two months later, at the end of the study. Fewer than half of the participants in the study started with elevated levels of CRP.
Participants who had baseline CRP levels less than 1 milligram per liter saw no significant effect on CRP levels after taking vitamin C supplements. However, those who started off with CRP levels of 1 milligram per liter or higher saw a 16.7 percent drop in levels after two months of treatment with vitamin C.
The researchers found no significant results for those taking vitamin E. They are uncertain as to why vitamin E did not show an effect even though it is also an antioxidant. Block noted that these vitamins have other functions independent of their antioxidant properties. Or, perhaps the difference relates to the fact that vitamin E is fat soluble and thus found in cell membranes while vitamin C  is water soluble and found in intercellular fluid, the researchers said.
Although this study ended at two months, Block noted that there is no evidence to date of adverse effects for longer-term use of vitamin C at high levels. At the same time, researchers acknowledged the need to study whether vitamin C's beneficial impact on CRP levels continue past two months.
"This is clearly a line of research worth pursuing," said Block. "It has recently been suggested by some researchers that people with elevated CRP should be put on statins as a preventive measure. For people who have elevated CRP but not elevated LDL cholesterol, our data suggest that vitamin C should be investigated as an alternative to statins, or as something to be used to delay the time when statin use becomes necessary."
The National Institutes of Health helped support this research.

Story Source:
Materials provided by University of California - Berkeley. Note: Content may be edited for style and length.

Why high-dose vitamin C kills cancer cells

 

Why high-dose vitamin C kills cancer cells

Low levels of catalase enzyme make cancer cells vulnerable to high-dose vitamin C

Date:
January 9, 2017
Source:
University of Iowa Health Care
Summary:
Cancer researchers have homed in on how high-dose vitamin C kills cancer cells. Vitamin C breaks down to generate hydrogen peroxide, which can damage tissue and DNA. The new study shows that tumor cells with low levels of catalase enzyme activity are much less capable of removing hydrogen peroxide than normal cells, and are more susceptible to damage and death when they are exposed to high doses of vitamin C.  
 
Vitamin C has a patchy history as a cancer therapy, but researchers at the University of Iowa believe that is because it has often been used in a way that guarantees failure.
Most vitamin C therapies involve taking the substance orally. However, the UI scientists have shown that giving vitamin C intravenously -- and bypassing normal gut metabolism and excretion pathways -- creates blood levels that are 100 -- 500 times higher than levels seen with oral ingestion. It is this super-high concentration in the blood that is crucial to vitamin C's ability to attack cancer cells.
Earlier work by UI redox biology expert Garry Buettner found that at these extremely high levels (in the millimolar range), vitamin C selectively kills cancer cells but not normal cells in the test tube and in mice. Physicians at UI Hospitals and Clinics are now testing the approach in clinical trials for pancreatic cancer and lung cancer that combine high-dose, intravenous vitamin C with standard chemotherapy or radiation. Earlier phase 1 trials indicated this treatment is safe and well-tolerated and hinted that the therapy improves patient outcomes. The current, larger trials aim to determine if the treatment improves survival.
In a new study, published recently in the December issue of the journal Redox Biology, Buettner and his colleagues have homed in on the biological details of how high-dose vitamin C (also known as ascorbate) kills cancer cells.
The study shows that vitamin C breaks down easily, generating hydrogen peroxide, a so-called reactive oxygen species that can damage tissue and DNA. The study also shows that tumor cells are much less capable of removing the damaging hydrogen peroxide than normal cells.
"In this paper we demonstrate that cancer cells are much less efficient in removing hydrogen peroxide than normal cells. Thus, cancer cells are much more prone to damage and death from a high amount of hydrogen peroxide," says Buettner, a professor of radiation oncology and a member of Holden Comprehensive Cancer Center at the University of Iowa. "This explains how the very, very high levels of vitamin C used in our clinical trials do not affect normal tissue, but can be damaging to tumor tissue."
Normal cells have several ways to remove hydrogen peroxide, keeping it at very low levels so it does not cause damage. The new study shows that an enzyme called catalase is the central route for removing hydrogen peroxide generated by decomposing vitamin C. The researchers discovered that cells with lower amounts of catalase activity were more susceptible to damage and death when they were exposed to high amounts of vitamin C.
Buettner says this fundamental information might help determine which cancers and which therapies could be improved by inclusion of high-dose ascorbate in the treatment.
"Our results suggest that cancers with low levels of catalase are likely to be the most responsive to high-dose vitamin C therapy, whereas cancers with relatively high levels of catalase may be the least responsive," he explains.
A future goal of the research is to develop methods to measure catalase levels in tumors.

Story Source:
Materials provided by University of Iowa Health Care. Note: Content may be edited for style and length.



Journal Reference:
  1. Claire M. Doskey, Visarut Buranasudja, Brett A. Wagner, Justin G. Wilkes, Juan Du, Joseph J. Cullen, Garry R. Buettner. Tumor cells have decreased ability to metabolize H2O2: Implications for pharmacological ascorbate in cancer therapy. Redox Biology, 2016; 10: 274 DOI: 10.1016/j.redox.2016.10.010

Benefits of high-dose vitamin C for ovarian cancer patients

 

Benefits of high-dose vitamin C for ovarian cancer patients

Date:
February 10, 2014
Source:
University of Kansas Cancer Center
Summary:
Researchers have found that a combination of infused vitamin C and conventional chemotherapy stopped ovarian cancer in the laboratory, and reduced chemotherapy-associated toxicity in patients with ovarian cancer.
Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.
By evaluating the therapy in cells, animals, and humans, the researchers found that a combination of infused vitamin C and the conventional chemotherapy drugs carboplatin and paclitaxel stopped ovarian cancer in the laboratory, and reduced chemotherapy-associated toxicity in patients with ovarian cancer. The results of their study have been published in the journal Science Translational Medicine.
"In the 1970s, ascorbate, or vitamin C, was an unorthodox therapy for cancer. It was safe, and there were anecdotal reports of its clinical effectiveness when given intravenously. But after oral doses proved ineffective in two cancer clinical trials, conventional oncologists abandoned the idea. Physicians practicing complementary and alternative medicine continued to use it, so we felt further study was in order," explains the study's senior author, Qi Chen, Ph.D., Assistant Professor in KU Medical Center's Department of Pharmacology, Toxicology and Therapeutics and the Department of Integrative Medicine. "What we've discovered is that, because of its pharmacokinetic differences, intravenous vitamin C, as opposed to oral vitamin C, kills some cancer cells without harming normal tissues."
The researchers' clinical trial involved 27 patients with newly diagnosed Stage 3 or Stage 4 ovarian cancer. All of the participants received conventional therapy with paclitaxel or carboplatin, while some were also treated with high-dose intravenous vitamin C. Researchers monitored the participants for five years. Those patients who received vitamin C tended to experience fewer toxic effects from the chemotherapy drugs.
In laboratory rodents, the scientists observed that vitamin C was able to kill cancer cells at the concentrations achievable only by intravenous infusion, with no observable toxicity or pathological changes in the liver, kidney or spleen.
Collaborating on the study at KU Medical Center were postdoctoral fellow Yan Ma and graduate student Kishore Polireddy in the Department of Pharmacology, Toxicology and Therapeutics; Jeanne Drisko, M.D., director of the Integrative Medicine program; and Julia Chapman, M.D., associate professor in the Department of Obstetrics and Gynecology. Collaborating with the team was Mark Levine, M.D., at the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health.
High-dose vitamin C is currently administered intravenously to thousands of patients by practitioners of complementary and alternative medicine. However, Drisko notes, conventional physicians remain skeptical about its therapeutic benefits. Given this current polarization of thought, the researchers sought to understand the cellular mechanisms by which pharmacologic vitamin C manifests its therapeutic benefit in cancer.
"We aimed to investigate the mechanisms of vitamin C-induced cell death in the laboratory. And in patients with ovarian cancer, we conducted an early phase clinical trial examining safety and toxicity of high dose intravenous vitamin C. We now have a better understanding of vitamin C's anti-cancer action, plus a clear safety profile, and biological and clinical plausibility with a firm foundation to proceed," Drisko says. "Taken together, our data provide strong evidence to justify larger and robust clinical trials to definitively examine the benefit of adding vitamin C to conventional chemotherapy."

Story Source:
Materials provided by University of Kansas Cancer Center. Note: Content may be edited for style and length.



Journal Reference:
  1. Y. Ma, J. Chapman, M. Levine, K. Polireddy, J. Drisko, Q. Chen. High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy. Science Translational Medicine, 2014; 6 (222): 222ra18 DOI: 10.1126/scitranslmed.3007154

Vitamin C related to reduced risk of cardiovascular disease, early death

 

Vitamin C related to reduced risk of cardiovascular disease, early death

Date:
July 7, 2015
Source:
University of Copenhagen The Faculty of Health and Medical Sciences
Summary:
High vitamin C concentrations in the blood from the intake of fruit and vegetables are associated with a reduced risk of cardiovascular disease and early death, new research shows.
New research from the University of Copenhagen and Herlev and Gentofte Hospital shows that high vitamin C concentrations in the blood from the intake of fruit and vegetables are associated with a reduced risk of cardiovascular disease and early death.
The study, which has just been published in the well known American Journal of Clinical Nutrition, is based on the Copenhagen General Population Study.
As part of the study, the researchers had access to data about 100,000 Danes and their intake of fruit and vegetables as well as their DNA. "We can see that those with the highest intake of fruit and vegetables have a 15% lower risk of developing cardiovascular disease and a 20% lower risk of early death compared with those who very rarely eat fruit and vegetables. At the same time, we can see that the reduced risk is related to high vitamin C concentrations in the blood from the fruit and vegetables," says Camilla Kobylecki, a medical doctor and PhD student at the Department of Clinical Biochemistry, Herlev and Gentofte Hospital.
Vitamin C from food rather than supplements
Among other things, vitamin C helps build connective tissue which supports and connects different types of tissues and organs in the body. Vitamin C is also a potent antioxidant which protects cells and biological molecules from the damage which causes many diseases, including cardiovascular disease. The human body is not able to produce vitamin C, which means that we must get the vitamin from our diet.
"We know that fruit and vegetables are healthy, but now our research is pinpointing more precisely why this is so. Eating a lot of fruit and vegetables is a natural way of increasing vitamin C blood levels, which in the long term may contribute to reducing the risk of cardiovascular disease and early death. You can get vitamin C supplements, but it is a good idea to get your vitamin C by eating a healthy diet, which will at the same time help you to develop a healthier lifestyle in the long term, for the general benefit of your health," says Boerge Nordestgaard, a clinical professor at the Faculty of Health and Medical Sciences, University of Copenhagen, and a consultant at Herlev and Gentofte Hospital.
The researchers are now continuing their work to determine which other factors, combined with vitamin C, have an impact on cardiovascular disease and death.

Story Source:
Materials provided by University of Copenhagen The Faculty of Health and Medical Sciences. Note: Content may be edited for style and length.

Big doses of vitamin C may lower blood pressure

Big doses of vitamin C may lower blood pressure

Image result for vitamin c
you need to go >>vitamin c today 
Taking large doses of vitamin C may moderately reduce blood pressure, according to an analysis of years of research by Johns Hopkins scientists. But the researchers stopped short of suggesting people load up on supplements.
"Our research suggests a modest blood pressure lowering effect with vitamin C supplementation, but before we can recommend supplements as a treatment for high blood pressure, we really need more research to understand the implications of taking them," says Edgar "Pete" R. Miller III, M.D., Ph.D., an associate professor in the division of general internal medicine at the Johns Hopkins University School of Medicine and leader of the study published in the American Journal of Clinical Nutrition.
Roughly 30 percent of adults in the United States have high blood pressure, or hypertension, an important risk factor for heart disease and stroke. Successful treatment may include drugs, exercise, weight loss, and dietary changes such as reducing salt intake. Some experts believe that large amounts of vitamin C, an essential micronutrient found primarily in fruits and vegetables, could lower pressure as well, but randomized, controlled dietary intervention studies -- the gold standard of nutrition research -- have produced mixed results.
Miller and his colleagues reviewed and analyzed data from 29 randomized, controlled, previously published clinical trials that reported systolic and/or diastolic blood pressure values and also compared vitamin C intake to a placebo. What they found is that taking an average of 500 milligrams of vitamin C daily -- about five times the recommended daily requirement -- reduced blood pressure by 3.84 millimeters of mercury in the short term. Among those diagnosed with hypertension, the drop was nearly 5 millimeters of mercury.
By comparison, Miller says, patients who take blood pressure medication such as ACE inhibitors or diuretics (so-called "water pills") can expect a roughly 10 millimeter of mercury reduction in blood pressure.
Five hundred milligrams of vitamin C is the amount in about six cups of orange juice. The recommended daily intake of vitamin C for adults is 90 milligrams.
"Although our review found only a moderate impact on blood pressure, if the entire U.S. population lowered blood pressure by 3 milliliters of mercury, there would be a lot fewer strokes," Miller says. Miller cautions, however, that none of the studies his team reviewed show that vitamin C directly prevents or reduces rates of cardiovascular disease, including stroke.
Scientists have focused on vitamin C's potential role in blood pressure reduction because of the nutrient's biological and physiological effects. For example, vitamin C may act as a diuretic, causing the kidneys to remove more sodium and water from the body, which helps to relax the blood vessel walls, thereby lowering blood pressure.
Nutritional supplements are a $28 billion-a-year industry, and marketing claims, newspaper stories and testimonials often make them hard to resist, Miller says. People often view supplements as a "natural alternative" and preferable to drugs for high blood pressure or other ailments, he adds, despite mounting evidence that many supplements don't work and in some cases may cause harm.
"People love to take vitamins regardless of the evidence or lack of it," Miller says. "We're trying to raise the bar and provide evidence-based guidance about whether supplements help or actually do harm." With respect to vitamin C, he says, the jury is still out.
Other study authors from Johns Hopkins include Stephen P. Juraschek, an M.D., Ph.D. candidate; Eliseo Guallar, M.D., Dr.Ph.; and Lawrence J. Appel, M.D., M.P.H.
you need to go >>vitamin c today 

Story Source:
Materials provided by Johns Hopkins Medicine. Note: Content may be edited for style and length.



Journal Reference:
  1. S. P. Juraschek, E. Guallar, L. J. Appel, E. R. Miller. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 2012; DOI: 10.3945/ajcn.111.027995